Drug Retail


  • Arena Pharmaceuticals CEO on Belviq  Tuesday, 11 Jun 2013 | 5:40 PM ET

    Arena Pharmaceuticals' new obesity drug Belviq hits the U.S. shelves today. Lonnel Coats, Eisai CEO, and Jack Lief, Arena CEO, discuss expectations for the drug.

  • The Worst Allergy Season Ever  Friday, 7 Jun 2013 | 2:45 PM ET

    Allergy season has been getting longer every year for 15 years, with Dr. Michael Foggs of American College of Allergy, Asthma and Immunology; and Stephen Brozak, WBB Securities, discusses the big money in the allergy business.

  • Real-Life 'Weeds'? Mom Is Accused Marijuana Dealer Wednesday, 5 Jun 2013 | 11:21 AM ET

    Andrea Sanderlin is not an actress, but her story—a horse-riding suburban mother of three accused of running a multimillion-dollar marijuana ring—sounds like a television show.

  • Coca-Cola Enters 'Frontier Market' Myanmar Tuesday, 4 Jun 2013 | 4:47 AM ET

    As Coca-Cola unveiled its first processing plant in Myanmar, one analyst warned that the move into frontier markets could mean emerging markets are not as attractive to multi-nationals as they once were.

  • All-American Pot Shop Chain?  Monday, 3 Jun 2013 | 2:51 PM ET

    Jamen Shively, a former Microsoft executive and currently CEO of Diego Pellicer, wants to build the first national marijuana store brand.

  • Rise In Melanoma Treatments  Monday, 3 Jun 2013 | 1:04 PM ET

    CNBC's Jackie DeAngelis reports on drug companies making headlines out of the American Society of Clinical Onocology conference. David Risinger of Morgan Stanley discusses the rise in melanoma treatments shown at this year's event.

  • Pressure Grows to Create Drugs for ‘Superbugs’ Monday, 3 Jun 2013 | 1:45 AM ET
    A hospital epidemiologist and a geneticist at the National Institutes of Health Clinical Center in Bethesda, Md.

    Government officials, drug companies and medical experts, faced with outbreaks of antibiotic-resistant "superbugs", are pushing to speed up the approval of new antibiotics, the NYT reports.

  • Stocks to Shrug Off Blood-Pressure Drug Dispute Friday, 31 May 2013 | 4:29 PM ET

    A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.

  • Faber Report: Royalty Pharma to Raise Elan Bid  Monday, 20 May 2013 | 10:32 AM ET

    A break down on the latest activity in mergers and acquisitions, with CNBC's David Faber.

  • What's Working in Pharma  Monday, 13 May 2013 | 6:15 PM ET

    Of the new drugs approved from 2004 through 2011, Quintiles was involved with 85 percent of the central nervous system drugs, 76 percent of oncology drugs and 72 percent of cardiovascular drugs. Mad Money host Jim Cramer explains why the stock is a buy.

  • Talking Numbers: Pfizer Flops Earnings  Tuesday, 30 Apr 2013 | 3:15 PM ET

    Technical analyst Jeff Tomasulo is bearish on Pfizer after its big drop today. Fundamental analyst Pat Dorsey also isn't a buyer. (2:25)

  • Novartis Disputes Allegations  Monday, 29 Apr 2013 | 1:11 PM ET

    CNBC's Andrea Day reports Swiss drug maker Novartis is disputing allegations in 2 U.S. federal lawsuits. The company is accused of wining and dining doctors.

  • Isis Takes on Huntington's Disease  Wednesday, 24 Apr 2013 | 5:40 PM ET

    Isis Pharmaceuticals CEO Stanley Crooke discusses his new technology Antisense and its role in helping huntington's disease.

  • J&J Tops Estimates on Newer Medicine Growth Tuesday, 16 Apr 2013 | 8:16 AM ET

    The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.

  • Global Growth Creates US Jobs: General Mills CEO Thursday, 11 Apr 2013 | 3:54 PM ET

    The "astonishing" growth of the middle class in emerging markets is benefiting General Mills and creating jobs in the U.S., CEO Ken Powell told CNBC's "Street Signs" on Thursday.

  • Red Hot Big Pharma Worth Owning  Tuesday, 9 Apr 2013 | 6:25 PM ET

    Not every stock needs to have a "turbo-charged" growth angle to it. Mad Money host Jim Cramer says big pharma stocks have been red hot, and discusses which ones are worth owning.

  • Johnson & Johnson, a Break-Up Play?  Monday, 8 Apr 2013 | 6:25 PM ET

    Investors should always have a high yielding stock in their portfolio. Big pharma stocks tend to do better when the economy isn't doing so well, explains Mad Money host Jim Cramer. A preview of Johnson & Johnson ahead of earnings.

  • Johnson & Johnson Hits All-Time High  Monday, 1 Apr 2013 | 2:38 PM ET

    Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.

  • Biogen IDEC CEO on Multiple Sclerosis Pill  Thursday, 28 Mar 2013 | 4:35 PM ET

    Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.

  • Pay For Generic Drug Delay  Monday, 25 Mar 2013 | 4:52 PM ET

    The government says big pharma should not be allowed to pay generic drug makers to let them keep their costly branded drugs on the market longer, reports CNBC's Bertha Coombs.